Merck & Co. has raised its revenue outlook, based on a notable rise in sales for 3Q2022. Sabela Ojea reported the revised projections in the Philadelphia Business Journal.

The new revenue projections for the North Wales entity have been lifted 14 percent based on sales of oncology treatments and vaccines.

At the quarter’s Sept. 30 end, sales were up $15 billion, outpacing market expectations of $14.1 billion, reported FactSet, a Conn. financial data and software company.

Communications from Merck cited the following revenue increases:

• 20 percent for its cancer treatment Keytruda
• 15 and 20 percent for rises for human papilloma virus vaccines Gardasil and Gardasil 9, respectively

Pharma company representatives said both metrics improved, owing to growth in U.S. and Chinese markets.

Given current levels of demand, Merck expects to end the year with worldwide sales of $58.5–$59 billion.

A deeper dive into the upbeat third quarter at Merck & Co. is at the Philadelphia Business Journal.